[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ageing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ageing":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,44,80,108,140,181,216,253,277,307,338,369,393,424,455,481,506],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644675","muscle-function-response-to-resistance-band-training-in-older-adults-with-impaired-muscle-power-100644675",false,"NCT07672834","Muscle Function Response to Resistance Band Training in Older Adults With Impaired Muscle Power","Inclusion Criteria:\n\n* Participants will be of male or female sex and free from known neurological health conditions (e.g. Peripheral Neuropathy, Parkinson's Disease, Stroke, Migraines, Epilepsy) or musculoskeletal injury.\n* low muscle power determined as a score of 8.1 and 9 seconds or more for the completion of the 5 times sit to stand test for males and females respectively\n\nExclusion Criteria:\n\n* Neurological health condition or musculoskeletal injury at the time of baseline testing\n* individuals aged under 50\n* individuals who have been told to avoid strenuous physical activity",true,"ALL","50 Years",{"count":19,"type":20},104,"ESTIMATED","INTERVENTIONAL",[23],"NA","To investigate the effect of an fitness advice and resistance band exercise intervention on balance, muscle function, and power in an older people population who have low muscle power.",[26],"Ageing",[28,29,30],"muscle power","Balance","functional movement","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2024-06-02",{"date":39,"type":20},"2027-10-30",{"name":41,"class":42},"Brunel University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":43},"100625207","this-study-investigates--hydroxy--methylbutyrate-hmb-and-2-hydroxybenzylamine-2-hoba-when-administered-either-individually-or-in-combination-contributes-to-an-increased-quality-of-health-specifically-improving-muscular-strength-and-cognitive-functioning-in-adults-over-the-age-of-65-100625207","NCT07419633","This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65.","The Effects of Beta-Hydroxy-Beta-methylbutyrate (HMB) and\u002For 2-hydroxybenzylamine (2-HOBA) on Markers of Health Span in Older Adults. A Randomized Control Trial.","H2AGE","Inclusion Criteria:\n\n•. 65 years of age\n\n* English or French speaking\n* Females not of childbearing potential\n* Willing to maintain current lifestyle and dietary habits, including level of physical activity, allowed medication\u002Fsupplements habits for the duration of the study\n\nExclusion Criteria:\n\n* Known cardiac diseases, known arterial fibrillation, hepatic diseases, immune diseases (e.g. Individuals with an acute infectious disease, autoimmune disease or are immune compromised), ulcers, asthma, gout, severe anemia, hay fever, nasal polyps.\n\n  * Chronic kidney disease \\[estimated glomerular filtration rate (GFR) \\\u003C 35 mL\u002Fmin\\].\n  * Neurological injury\u002Fdisorder with significant persistent neurological or functional deficit (e.g., stroke with hemiparesis, spinal cord injury, muscular dystrophy, myopathy, myasthenia gravis, Parkinson's disease, peripheral polyneuropathy).\n  * Neuropsychological condition and\u002For cognitive impairment that, in the QI's opinion, could interfere with study participation\n  * History of confirmed chronic obstructive pulmonary disease with a severity grade \\> 2 on the Medical Research Council Dyspnea Scale.\n  * Uncontrolled hypothyroidism or hyperthyroidism. Hypothyroid patients who have changed their dose of hormone replacement therapy in the 6 weeks before screening are not eligible.\n  * Underlying muscle diseases, including a history of or currently active myopathy (e.g., dermatomyositis, polymyositis, etc.) or muscular dystrophies.\n  * Confirmed rheumatoid arthritis, acquired immunodeficiency syndrome (AIDS), type 1 or type 2 diabetes mellitus.\n  * History of cancer in the last 6 months.\n  * Not on any medications including NHPs\u002Fliving with medical conditions that would compromise the study outcome or the safety of the research participant.\n  * Known allergy to study medication or its components (non-medicinal ingredients).\n  * Allergy to aspirin\u002Fsalicylate or if using other drugs containing acetylsalicylic acid or other salicylates and a history of ASA-sensitive asthma\u002Fbronchospasm\n\nThe following list of medications\u002FNHPs will be excluded (and weaned as seen necessary by the study physician) prior to and during the study:\n\n* Participants on newly initiated cholesterol-lowering medication will be excluded. Those on stable regimens for ≥3 months will be included and will be monitored for potential interactions as per the HMB monograph.\n* Medications associated with muscle weakness or immune effects (i.e., oral glucocorticoids).\n* Medications or supplements affecting skeletal muscle metabolism or weight including: Use of MAO-I's (monoamine oxidase inhibitors), additional consumption of 2-HOBA, Vitamin D or HMB, anabolic steroids, selective androgen receptor modulators (SARMs), corticosteroids, GLP-1s, or other weight loss medications).\n* Excessive protein supplementation (i.e., \\>2.0 g\u002Fkg\u002Fday).\n* All participants must be on a stable dose of allowed supplements\u002Fmedications for at least 3 months prior to enrollment. All concomitant therapies will be documented.\n\nNon-pharmacological interventions that could influence study outcomes (e.g., pulmonary rehabilitation, structured exercise programs) will not be permitted.\n\nParticipants undergoing such therapies will be excluded. Any new interventions started during the study must be reported and if judged inappropriate, will result in withdrawal from the trial.","65 Years",{"count":54,"type":20},120,[23],"In this study, participants will be assigned to receive HMB, 2-HOBA, a combination of both, or a comparison supplement for a set period of time. During the study, participants will attend scheduled visits where researchers will assess muscle strength, physical function, and overall health. Blood samples may be collected to measure markers related to metabolism, inflammation, and oxidative stress. Study staff will also monitor safety and any side effects throughout the study.",[58,59,60,61,26],"Muscle","Cognitive Functioning","Geriatric","Ageing and Geriatric Health",[63,58,64,65,66,67,68,69,70],"Health","Cognitive","Memory","natural product","ageing","natural","supplement","preservation","2026-05-11",{"date":73,"type":35},"2026-05-14",{"date":75,"type":35},"2026-03-06",{"date":77,"type":20},"2027-02-05",{"name":79,"class":42},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":15,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":43},"100562119","swallowing-difficulties-in-people-over-60-years-prevalence-degree-of-difficulty-and-intervention-100562119","NCT06599021","Swallowing Difficulties in People Over 60 Years: Prevalence, Degree of Difficulty and Intervention","Inclusion Criteria:\n\n* Participation in SCAPIS2\n* Swallowing dysfunction according to timed water swallow test or\n* Swallowing dysfunction according to self-report\n\nExclusion Criteria:\n\n* Severely impaired intellectual abilities.\n* Inability to consent to inclusion in the study.\n* Inability to answer written questionnaires in Swedish\n\nInclusion of non-dysphagia control cohort: No signs of aspiration, slow swallowing (\\<10 ml\u002Fsec) or self-rated difficulties with eating and swallowing in sub-study SCAPIS2","18 Years",{"count":88,"type":20},99,[23],"Participants included in SCAPIS2 (Swedish Cardio Pulmonary bioimage study) are screened regarding swallowing difficulty using a timed water swallow test. Participants who show signs of swallowing difficulty (dysphagia) are included in the present study, which encompasses s flexible endoscopic evaluation of swallowing function (FEES). Participants showing a moderate-severe dysphagia are randomized into one of three intervention groups: muscle strengthening training, skill-based swallowing training and a control group who will receive compensatory treatment. The study is expected to improve diagnostics and treatment of swallowing difficulties in an ageing population.",[92,93,26],"Dysphagia","Intervention",[92,95,96,97,98],"Age-related dysphagia","Health-related quality of life","Dysphagia intervention","Dysphagia characteristics","2026-04-22",{"date":101,"type":35},"2026-04-27",{"date":103,"type":35},"2024-12-01",{"date":105,"type":20},"2028-04",{"name":107,"class":42},"Lisa Tuomi",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100568101","effectiveness-of-the-who-icope-integrated-care-for-older-people-program-in-preventing-age-related-functional-decline-icope-trialfr-100568101","NCT06676839","Effectiveness of the WHO ICOPE (Integrated Care for Older People) Program in Preventing Age-related Functional Decline (ICOPE Trial.Fr)","Effectiveness of the WHO ICOPE (Integrated Care for Older People) Program in Preventing Age-related Functional Decline: a 36-month Randomized Controlled Trial With a 24-month Extension","ICOPE Fr","Inclusion Criteria:\n\n1. Participants aged 65 years and older.\n2. Participants living independently at home (ADL = 6, except for an occasional urinary abnormality which will be accepted).\n3. Participants showing functional decline in at least 2 of the 6 functional domains of ICOPE (mobility, cognition, nutrition, vision, hearing, and psychological well-being) identified using the ICOPE screening tool.\n4. Participants affiliated with a social protection system.\n\nExclusion Criteria:\n\n1. Participants who has already benefited from the ICOPE program or who has completed more than one isolated step 1\n2. Participants living in a dependent elderly care facility.\n3. Participants with a disability preventing them from reaching the trial examination center without assistance (such as dementia or significant mobility impairment).\n4. Participants with hearing, visual, or speech impairments preventing them from understanding instructions or communicating with study staff.\n5. Participants with a life-threatening illness with a prognosis of less than 5 years.\n6. Participants unable to provide informed written consent.\n7. Participants under legal protection, guardianship, or trusteeship.\n8. Participants participating in another interventional research study.\n9. Participants in a relationship with a person participating in the study.",{"count":117,"type":20},1000,[23],"The World Health Organization (WHO) has designed an integrated care program (ICOPE) aimed at maintaining the functions of elderly people to preserve their autonomy. It includes four steps (Screening, Comprehensive Assessment, Personalized Prevention and Care Plan, Follow-up). The screening tool assesses a person's intrinsic capacity in six key functional domains (mobility, cognition, nutrition, vision, hearing, psychological well-being). This screening can be conducted by a professional or through self-assessment using the digital application (ICOPE Monitor). If a deficit is detected, an alert is issued, and if confirmed by a healthcare professional trained in ICOPE, a comprehensive assessment of the impaired function and a personalized prevention and care plan is proposed by the physician. A trained nurse assists the person in implementing this plan in collaboration with the primary care physician and local professionals. When multiple functions are impaired, it is recommended to conduct a thorough evaluation of all six functions to implement an integrated approach.\n\nThe clinical effectiveness of the program in preventing functional decline has not yet been established in a sufficiently long trial.\n\nThe investigators propose to evaluate the effect and cost of the ICOPE program in France through a controlled trial. Our hypothesis is that, in the current primary care context, the comprehensive implementation of the program (combining regular screening, comprehensive assessment, prevention and care plan, and follow-up) is necessary to more effectively prevent age-related functional decline compared to the usual care provided by the primary care physician.",[26],[122,123,124,125,126,127,128,129],"ICOPE","PREVENTION","intrinsic capacity","healthy ageing","integrated care","elderly","functional decline","Multi component prevention program","2026-03-18",{"date":132,"type":35},"2026-03-23",{"date":134,"type":35},"2024-10-14",{"date":136,"type":20},"2031-10-31",{"name":138,"class":42},"University Hospital, Toulouse",6,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":160,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":43},"100628795","l-serine-and-strength-training-in-the-elderly-100628795","NCT07466290","L-serine and Strength Training in the Elderly","AAAging","Inclusion Criteria:\n\n* Men and women between the ages of 65 and 85\n* Mini-Mental-State \\>23\n* Independently mobile, without aids (walker, cane, etc.)\n\nExclusion Criteria:\n\n* Chronic diseases that contraindicate medical training therapy\n* Regular strength training (\\>1x\u002Fweek) in the last 6 months before confinement\n* Frailty Index ≥ 3\n* Lack of written consent to test physical performance\n* Regular use of Cortison-containing medications or Antibiotika\n* MR-specific exclusion criteria: claustrophobia, metal equipment or other magnetic Material in or on the body\n* Non-compliance with the study protocol: \\\u003C70% of the planned L-serine administration, \\\u003C70% of the strength training","85 Years",{"count":149,"type":20},126,[23],"This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people.\n\nHealthy, independent women and men aged 65 to 85 are eligible to participate. Participants will be randomly assigned to one of three groups: placebo, L-serine, or L-serine combined with strength training.\n\nCognitive tests, physical performance tests, and blood and brain tests will be conducted over a period of 48 weeks. The aim is to gain a better understanding of how nutrition and exercise can contribute to healthy aging.",[153,154,155,156,157,26,158,65,159],"Brain Health","Longevity","Cognitive Performance","Strength Training Effects","Healthy Ageing","Cognition","Muscle Strength",[157,161,162,163,164,165,166,65,167,168,169,170,171,172],"Brain ageing","Older adults","L-serine supplementation","Resistance training","Cognitive function","Cognitive ageing","Hippocampus","Magnetic resonance imaging","Electroencephalography","Brain connectivity","Muscle strength","Synaptic plasticity",{"date":174,"type":35},"2026-03-12",{"date":176,"type":20},"2026-03",{"date":178,"type":20},"2028-12",{"name":180,"class":42},"University of Vienna",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":43},"100627658","precision-geromedicine-tailored-healthy-ageing-with-lifestyle-supplements-and-drugs-prometheus-100627658","NCT07451496","PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)","PROMETHEUS","Inclusion Criteria:\n\n* Age 50-80 years (both male and female)\n* Relatively healthy and in stable health condition\n* Not engaged in regular resistance or aerobic training in the past 12 months (i.e., untrained)\n* VO₂peak below the 75th percentile for age- and sex-specific norms\n* Cognitive performance below 75th percentile on the NIH Toolbox Cognitive Function Battery\n* Willing and able to comply with exercise and supplementation protocols\n* English-literate (can read and understand English)\n* Provides written informed consent\n* Deemed to have mental capacity, as assessed by the Principal Investigator\n* Are able to attend all research visits for screening and research data collection at MD11, Yong Loo Lin School of Medicine, National University of Singapore\n\nExclusion Criteria:\n\n* Significant change in medication in the past 3 months\n* History of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke)\n* More than two unstable chronic conditions (e.g., hypertension, diabetes, osteoarthritis, COPD)\n* Known allergies to soy, shellfish\u002Fseaweed, mushrooms, or supplement ingredients\n* Participation in another interventional clinical trial\n* Current use of any study-related supplement unless willing to stop\n* Any medical, psychiatric, or cognitive condition deemed by the PI to jeopardise safety or compliance\n* Pregnant or planning pregnancy during the study period\n* Any conditions deemed by PI that jeopardize the safety or study compliance","80 Years",{"count":190,"type":20},20,[23],"As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide. Current therapeutic strategies often target individual diseases and decrease mortality without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process itself could prevent, delay, or manage the severity of multiple age-related diseases concurrently, thereby improving overall healthspan and reducing healthcare burdens.\n\nEmerging research highlights several interconnected hallmarks of aging, such as mitochondrial dysfunction, chronic inflammation, impaired autophagy, and immune dysregulation, as modifiable through targeted interventions. Precision geromedicine represents a paradigm shift in addressing these processes, combining baseline diagnostics with individualized treatment strategies that adapt over time based on patient response. This approach integrates lifestyle modifications, dietary supplements, and pharmacological agents to optimize physical, cognitive, and immune function across the lifespan .",[26],[195,196,197,198,199,200,201,202,203,204,205,206],"Whey Protein supplementation","Creatine","Fucoidan","NMN","Multivitamin","Ergothioneine","Urolithin A","Aging","Geroscience","DNA methylation","Healthspan","Epigenetic aging clock","2026-02-28",{"date":209,"type":35},"2026-03-05",{"date":211,"type":35},"2025-09-29",{"date":213,"type":20},"2026-06-30",{"name":215,"class":42},"National University of Singapore",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":15,"sex":16,"minAge":223,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":226,"briefSummary":227,"conditions":228,"keywords":232,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100625564","physiotherapy-interventions-on-functional-capacity-balance-and-mental-domains-in-community-dwelling-older-adults-a-randomized-clinical-trial-with-two-parallel-groups-100625564","NCT07424274","Physiotherapy Interventions on Functional Capacity, Balance and Mental Domains in Community-Dwelling Older Adults: A Randomized Clinical Trial With Two Parallel Groups","Randomized Clinical Trial of Multicomponent and Functional Exercise Protocols on Functional Capacity, Muscle Strength, Balance and Mental Health in Community-Dwelling Older Adults in Angola","Inclusion Criteria:\n\nAge ≥60 years. Community-dwelling older adults recruited from the Viana Rehabilitation Center and surrounding community in Luanda, Angola.\n\nAble to ambulate independently (with or without assistive devices). Able to understand and follow simple instructions (adequate hearing and cognitive capacity for participation).\n\nWilling and able to attend supervised exercise sessions three times per week for 12 weeks.\n\nProvides written informed consent.\n\nExclusion Criteria:\n\nClinically unstable medical conditions (e.g., decompensated heart failure, uncontrolled hypertension, acute infection, or other conditions making exercise unsafe).\n\nRecent stroke or other acute neurological event with unstable clinical status. Severe neurodegenerative disease with significant disability (e.g., advanced dementia or severe Parkinson's disease).\n\nAny medical contraindication to moderate-intensity exercise as judged by a physician\u002Fclinical team.\n\nParticipation in a structured exercise program in the last 3 months.\n\n\\-","60 Years",{"count":225,"type":20},350,[23],"This study will investigate whether two different physiotherapy exercise programs can improve physical function, balance and mental well-being in older adults living in the community in Angola.\n\nA total of 350 people aged 60 years or older will take part in the study. Participants will be randomly assigned to one of two supervised exercise programs. One group will participate in a multicomponent exercise program that includes strength, balance, walking and coordination exercises. The second group will participate in a reduced functional exercise program focused on basic strengthening, walking and simple daily activities. Both programs will be performed three times per week, with each session lasting 60 minutes, over a period of 12 weeks.\n\nParticipants will be assessed before and after the exercise program. The assessments will include tests of balance, muscle strength, walking ability and questionnaires about daily activities and mental health. Information about falls, blood pressure and general health will also be collected.\n\nThe goal of this study is to identify effective and safe physiotherapy strategies to help older adults maintain independence, reduce the risk of falls and support healthy ageing, especially in settings with limited health resources.",[26,229,230,231],"Frailty","Sarcopenia","Decline, Cognitive",[162,233,234,235,236,29,171,237,238,239,240,241,242],"Physiotherapy","aging","Exercise Therapy","Multicomponent exercise","handgrif strenght","Calf Circunferemce","mental health","community dwelling older adults","fall prevention","Activities of daily living","NOT_YET_RECRUITING","2026-02-13",{"date":246,"type":35},"2026-02-20",{"date":248,"type":20},"2026-02-15",{"date":250,"type":20},"2026-05-20",{"name":252,"class":42},"Aveiro University",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":147,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":262,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":43},"100596698","icope-intense-k-pilot-study-100596698","NCT07048860","ICOPE INTENSE-K Pilot Study","A ICOPE Intense Program Combined With Ketone Ester Pilot Study","Inclusion Criteria:\n\n* Independent-living (ADL ≥5\u002F6)\n* Men and women\n* Mobility impairment (5 Chair-rise test \\>12 seconds)\n* Sedentarism (spend six or more hours per day sitting or lying down)\n* Positive screening for cognitive impairment according to the ICOPE screening tool with MMSE \\[25-28\\]\n* BMI ≥25 kg\u002Fm2\n\nExclusion Criteria:\n\n* Unintentional weight loss (≥10%) in past 6 months\n* Dementia\n* Life-threatening illnesses, with a life expectancy (judged by the investigating doctor) of less than 1 year\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina or any other contraindication to physical activity (as determined by a physician) or comorbid disease that would impair ability to participate in the ICOPE intense intervention such as renal failure on hemodialysis, severe psychiatric disorder (depressive participant will not be excluded)\n* Organizational inability (three-time per week during the 60 days)\n* Living in a Nursing-Home\n* Under legal protection measure (guardianship, curatorship, safeguard of justice",{"count":261,"type":20},40,[23],"ICOPE could constitute the reference model of care for healthy aging. More specifically, our hypothesis is that the intervention implemented in ICOPE may directly or indirectly prevent immuno-senescence, the loss of mobility and the cognitive decline. In future Geroscience clinical trials, ICOPE-Intense could become a benchmark to reduce the rate of aging with a strong non-pharmacological intervention and state a reference intervention to compare with new gerotherapeutic drugs.",[26],[266,267,124,268],"cognition","morbility","biomarker of aging","2025-07-22",{"date":271,"type":35},"2025-07-23",{"date":273,"type":35},"2025-07-09",{"date":275,"type":20},"2025-12-31",{"name":138,"class":42},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":15,"sex":16,"minAge":284,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":43},"100599908","the-effects-of-age-on-muscle-endurance-during-resistance-exercise-with-and-without-blood-flow-restriction-100599908","NCT07090603","The Effects of Age on Muscle Endurance During Resistance Exercise With and Without Blood Flow Restriction","Age-Related Differences in Skeletal Muscle Endurance Responses to Various Relative Loads of Dynamic Resistance Exercise With and Without Peripheral Blood Flow Occlusion","Inclusion Criteria:\n\n* Able to understand and communicate in English\n* 19-35 years of age\n* 65 years of age or older\n* All \"No\" answers on the CSEP Get Active questionnaire or doctors' approval to participate\n\nExclusion Criteria:\n\n* BMI lower than 18 or greater than 32\n* Current use of cigarettes or other nicotine devices\n* Any major uncontrolled cardiovascular, muscular, metabolic, and\u002For neurological disorders\n* Any medical condition impacting the ability to participate in maximal exercise\n* Type one or type two diabetes\n* Diagnosis of cancer or undergoing cancer treatment in the past 12 months\n* Taking blood-thinning medication or the presence of a bleeding disorder\n* Drug therapy with any drugs that alter skeletal muscle metabolism (i.e., Metformin, Benzodiazepines)\n* Lowest calculated exercise testing load is less than the lightest weight able to be provided by the lab gymnasium equipment\n* In the past six months, completing more than 300 minutes of moderate physical activity or 150 minutes of vigorous physical activity per week\n* In the past six months, completing less than 150 minutes of moderate physical activity or 75 minutes of vigorous physical activity","19 Years",{"count":190,"type":20},[23],"The purpose of this study is to learn how aging affects muscle endurance during resistance exercise, and how oxygen delivery to the muscles plays a role in these changes. To answer this question, we are comparing how many repetitions of a leg exercise (knee extensions) younger and older adults can do at different exercise intensities. We will also look at how the muscles use oxygen during these exercises.\n\nParticipants will take part in 12 different exercise sessions. In each session, they will perform as many knee extensions as possible using different amounts of weight-consisting of 20%, 30%, 40%, 50%, 60% and 70% of the maximum weight they can lift one time. Each weight will be tested both with and without a cuff on the leg that temporarily reduces blood flow to the muscle.",[26,289],"Muscle Fatigue Caused by Repetitive Muscle Exercise",[291,292,293,294,295,67,296,297],"muscle endurance","muscle contraction","critical occluding tension","muscle oxygenation","NIRS","muscle fatigue","contraction induced occlusion","2025-07-21",{"date":300,"type":35},"2025-07-29",{"date":302,"type":20},"2025-09",{"date":304,"type":20},"2026-04",{"name":306,"class":42},"University of British Columbia",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":21,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":43},"100598503","promoting-mental-and-cognitive-health-in-old-age-through-scalable-evidence-based-interventions-100598503","NCT07072338","Promoting Mental and Cognitive Health in Old Age Through Scalable Evidence-based Interventions","PROMISE: Promoting Mental and Cognitive Health in Old Age Through Scalable Evidence-Based Interventions - Study Protocol for a Randomized Controlled Trial","PROMISE","Inclusion Criteria:\n\n* Aged 65 years or older.\n* Ability to speak and read the official language of their place of residence (French or German).\n* Ability to use and access a digital device for a digital training platform provided for the training.\n\nExclusion Criteria:\n\n* Aged below 65.\n* Inability to use and lack of access to a digital device required for using the digital training platform.",{"count":117,"type":20},[23],"Mental and cognitive health are key determinants of healthy and successful aging. These two domains are closely intertwined: while chronic stress can impair cognitive functioning, cognitive decline may in turn heighten stress and reduce overall well-being in older adults. This project aims to evaluate the effectiveness and scalability of a multidomain intervention to support mental and cognitive health in older adults. A single-blind, randomized, controlled 2×2 factorial trial will be conducted with a large sample of community-dwelling adults aged 65 years and older in the German- and French-speaking regions of Switzerland. Participants will be randomly assigned to one of four intervention arms: (1) WHO Self-Help Plus stress management training (SH+), (2) multidomain cognitive training focused on lifestyle and behavior change (COG), (3) a combined SH+ and COG intervention (SH+\u002FCOG), or (4) an active control group (CG) involving podcast listening and discussion. All interventions will include in-person group sessions, while the SH+, COG, and SH+\u002FCOG arms additionally offer a digital platform for self-guided home training. Primary outcomes (mental and cognitive health), secondary outcomes and moderators (cognitive functioning, stigma, self-efficacy, self-concept, loneliness, digital literacy, cognitive reserve, sociodemographic variables) will be assessed at baseline, post-intervention (10 weeks), and at 2- and 6-month follow-ups through a self-administered ambulatory assessment.",[319,158,26],"Well-Being, Psychological",[321,239,322,323,324,325,326,327,328],"well-being","cognitive health","healthy aging","cognitive function","stress-management training","Acceptance and commitment therapy","cognitive training","lifrstyle intervention","2025-07-15",{"date":331,"type":35},"2025-07-18",{"date":333,"type":20},"2026-01-01",{"date":335,"type":20},"2028-06-30",{"name":337,"class":42},"University of Geneva, Switzerland",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":15,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":43},"100599037","comparing-vascular-responses-to-aerobic-exercise-with-and-without-blood-flow-restriction-in-young-and-older-adults-100599037","NCT07079280","Comparing Vascular Responses to Aerobic Exercise With and Without Blood Flow Restriction in Young and Older Adults","Comparison of Acute Micro- and Macrovascular Responses to Aerobic Exercise With and Without Blood Flow Restriction in Young and Older Adults: A Randomized Crossover Trial.","UNDER PRESSURE","Inclusion Criteria:\n\n* Aged between 18-30 years and those over 60 years.\n\nExclusion Criteria:\n\n* Past or current history of coronary heart disease, stroke, oncological disease, or major cardiovascular events.\n* Individuals who had undergone surgery within the last two months\n* Body mass index (BMI) greater than 30 kg\u002Fm²\n* Declared sleep apnea\n* Active kidney or liver disease\n* Active tobacco smokers\n* Sensory impairments\n* Neurological or orthopedic functional impairments, musculoskeletal pathologies affecting exercise capacity\n* Physically active for more than six months with a weekly activity level of 1,000 MET\u002Fmin.",{"count":347,"type":20},52,[23],"Aging is a major risk factor for cardiovascular disease (CVD), contributing to progressive macrovascular and microvascular dysfunction. Macrovascular impairments, such as arterial stiffening and endothelial dysfunction, reduce nitric oxide (NO) bioavailability, leading to hypertension and impaired blood flow regulation. Microvascular dysfunction exacerbates cardiovascular decline by compromising capillary perfusion and tissue oxygenation, increasing susceptibility to ischemic events. Preserving vascular function is essential for maintaining cardiovascular health in aging populations.\n\nLow-intensity aerobic exercise (LIAE) improves cardiovascular health and mobility, particularly in populations unable to perform high-intensity exercise. However, LIAE alone often fails to induce significant vascular adaptations, such as improved arterial compliance or endothelial function, highlighting the need for optimized interventions.\n\nBlood Flow Restriction (BFR) enhances vascular adaptations during low-intensity exercise by inducing localized hypoxia, stimulating endothelial function and arterial remodeling. While BFR may transiently increase blood pressure and arterial stiffness, its vascular benefits resemble those of high-intensity exercise at lower workloads. However, research on BFR's acute vascular effects during aerobic exercise in older adults remains limited.\n\nCurrent studies have focused on perceptual and hemodynamic responses to LIAE+BFR but lack direct assessments of macrovascular (e.g., flow-mediated slowing) and microvascular function. Older adults may exhibit distinct vascular responses, yet data are scarce. This study examines acute vascular responses to LIAE+BFR and high-intensity interval exercise (HIIE) in young and older adults.\n\nHypothesis:\n\n1. BFR combined with LIAE will elicit greater acute microvascular and macrovascular responses in older adults than in younger adults.\n2. These responses will be comparable to HIIE without BFR, suggesting BFR enhances LIAE's efficacy to high-intensity levels.\n3. Any transient vascular dysfunction (e.g., increased arterial stiffness) will normalize within 30 minutes post-exercise, supporting safety in aging populations.",[26,351],"Blood Flow Restriction (BFR) Training Effects",[353,354,355,356,357,358,359,360],"Aerobic Exercise","Blood Flow Restriction","Microvascular Function","Flow mediated Slowing","Arterial Stiffness","Central Blood Pressure","Young Adults","Older Adults","2025-07-13",{"date":271,"type":35},{"date":364,"type":20},"2025-10-06",{"date":366,"type":20},"2026-07-31",{"name":368,"class":42},"Egas Moniz - Cooperativa de Ensino Superior, CRL",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":15,"sex":16,"minAge":86,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":21,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":392},"100577127","exploratory-study-on-the-role-of-vitamin-c-in-promoting-health-in-middle-aged-and-elderly-adults-100577127","NCT06794255","Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults","Randomized Controlled Trial on Vitamin C Supolementation for HealthRegulation in Middle-Aged and Elderly Adults","VitC-Aging","Inclusion Criteria:\n\n* Age: 55-65 years (for the experimental and control groups) or 18-70 years (for the baseline control group assessing aging changes).\n* Health Status: Deemed to be in good health based on medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.\n* Weight: BMI within the range of 18.5-28 kg\u002Fm².\n* Informed Consent: Capable of signing the informed consent form and complying with the requirements and restrictions outlined in the study protocol.\n\nExclusion Criteria:\n\n* Disease Status:Uncontrolled medical conditions or any disease that, in the investigator's opinion, may pose an inappropriate risk or contraindication or interfere with the study's objectives, conduct, or evaluation.Severe chronic or acute diseases (e.g., cancer, heart failure, renal insufficiency, COPD, diabetes, active liver disease, metabolic acidosis, poorly controlled hypertension, epilepsy, recent cardiovascular events, inflammatory bowel disease, neurological disorders, infectious diseases, severe autoimmune diseases, etc.).\n* Weight: BMI \\\u003C 18.5 or BMI \\> 28.\n* Substance\u002FAlcohol Abuse: Ongoing alcohol or drug abuse, or excessive alcohol consumption.\n* Medical History: History of gastrointestinal diseases, hyperuricemia, kidney or urinary tract stones, glucose-6-phosphate dehydrogenase deficiency, or paroxysmal nocturnal hemoglobinuria.\n* Allergy: Allergy to vitamin C or any component of its formulation.\n* Recent Medication Use: Use of high-dose vitamin C, vitamin E, low-dose aspirin, acarbose, metformin, NMN\u002FNR, or other anti-aging\u002Fweight-loss drugs within the past 3 months.\n* Informed Consent: Inability to provide informed consent.\n* Other: Any physical condition that, in the investigator's opinion, may adversely affect the study process or outcomes.\n* Clinical Research Participation: Participation in any other clinical research within 3 months prior to screening or during the study period, or receipt of chemotherapy, radiotherapy, biologic therapy, small-molecule therapeutic agents, or investigational drugs, with incomplete recovery from related side effects (excluding alopecia or potential neuropathy).","70 Years",{"count":379,"type":20},400,[23],"The purpose of this clinical trial is to understand whether oral vitamin C can help delay the aging of middle-aged and elderly individuals, search for sensitive biomarkers of human aging, and provide new paradigms and scientific guidance for aging intervention with small molecule drugs. The main questions it aims to answer are as follows:\n\n* Can oral vitamin C effectively improve the aging-related indicators?\n* What is the safety of participants when taking vitamin C supplements?\n\nResearchers will compare vitamin C with a placebo to observe whether vitamin C is effective in intervening in the aging of middle-aged and elderly individuals. Participants need to:\n\n* Take 2 tablets (250mg\u002Ftablet) of vitamin C or placebo after breakfast and dinner every day for 12 consecutive months;\n* Go to the designated place for a face-to-face follow-up every 6 months and receive a telephone follow-up every 2 months, and pick up subsequent drugs during the follow-up;\n* Honestly inform the medication situation during each follow-up;\n* Report any discomfort or adverse reactions that occur during the treatment process to the researchers;\n* Fill in a questionnaire about their own health status during each follow-up;\n* After 6 months and 12 months of intervention, conduct a comprehensive health examination as required, including blood tests and other items.",[26],"2025-06-23",{"date":385,"type":35},"2025-06-27",{"date":387,"type":35},"2025-04-02",{"date":389,"type":20},"2027-01-30",{"name":391,"class":42},"Peking University Third Hospital",3,{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":15,"sex":16,"minAge":400,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":21,"phases":403,"briefSummary":404,"conditions":405,"keywords":409,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":4},"100592310","investigating-the-effectiveness-of-a-2-week-novel-non-invasive-brain-stimulation-technique-on-cognitive-outcomes-in-healthy-adults-100592310","NCT06991764","Investigating the Effectiveness of a 2-week Novel Non-invasive Brain Stimulation Technique on Cognitive Outcomes in Healthy Adults","Investigating the Effectiveness of a 2-week High-frequency Transcranial Pulsed-current Stimulation on Cognitive Outcomes in Healthy Adults: A Randomised, Double Blinded, Sham-controlled Study","Inclusion Criteria:\n\n* Male and female young (21 to 30 years) and older adults (60 to 75 years)\n* Right-handed\n* Must be a native English speaker\n* No clinical diagnosis of neurodevelopmental, mood, neurological or neurodegenerative disorders\n* Adults with cardiometabolic or cardiovascular conditions may participate if their condition is controlled and stable with medication and \u002F or lifestyle interventions\n\nExclusion Criteria:\n\n* Currently on long-term medication for pain or migraines \u002F headaches\n* Adults with metallic implants in the chest or head region\n* Adults with epilepsy, or known seizure or immediate family members that have had a seizure before\n* Had a recent head injury that resulted in a temporary loss of consciousness or of memory in the last 12 months\n* Had prior head surgery\n* Prone to fainting\n* Sensitive skin or prone to skin allergies","21 Years","75 Years",{"count":54,"type":20},[23],"The goal of this randomised controlled trial is to investigate the effects of a 2-week high-frequency transcranial pulsed current stimulation (tPCS) on cognitive outcomes in older and healthy adults. The main questions it aims to answer are:\n\n1. Would a single session of anodal tPCS over the left prefrontal cortex improve working memory, task inhibition, and task switching in healthy young and older adults, compared to anodal transcranial direct current stimulation (tDCS) and sham-tPCS?\n2. Would repeated session of anodal-tPCS (2-weeks) lead to improvements in working memory, task inhibition, and task switching in healthy young and older adults, compared to tDCS and sham-tPCS?\n3. Will tPCS be better tolerated among healthy adults, compared to tDCS?\n\nResearchers will compare tPCS \u002F tDCS \u002F sham-tPCS to see if there are any differences in cognitive outcomes after 1 session and after repeated sessions, as well as to compare the tolerance of tPCS against tDCS and sham-tPCS.\n\nParticipants will be requested to:\n\n* Undergo 1 of 3 of the following conditions: tDCS \u002F tPCS \u002F sham-tPCS\n* Complete three sessions of cognitive tasks testing working memory, inhibition and task switching at baseline (pre-stimulation), after day 1 of brain stimulation and after 10 sessions of brain stimulation (post- repeated stimulation)\n* Undergo fNIRS-EEG brain measurements concurrently with the cognitive tasks",[406,26,407,408],"Transcranial Direct Current Stimulation (tDCS)","Executive Functioning","Transcranial Electric Stimulation",[410,411,407,412,413,414,26],"Randomised Controlled Trial","Non-Invasive Brain Stimulation","Transcranial Direct Current Stimulation","Transcranial Pulsed Current Stimulation","Healthy Adults","2025-05-18",{"date":417,"type":35},"2025-05-28",{"date":419,"type":20},"2025-06-01",{"date":421,"type":20},"2027-04-30",{"name":423,"class":42},"Nanyang Technological University",{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":377,"maxAge":432,"enrollmentInfo":433,"targetDuration":4,"studyType":435,"phases":4,"briefSummary":436,"conditions":437,"keywords":441,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":43},"100591474","physical-activity-oxidative-stress-and-inflammation-with-ageing-100591474","NCT06980896","Physical Activity Oxidative Stress and Inflammation With Ageing","Exploratory Pathophysiological Study on the Association Between Physical Performance and Biomarkers of Oxidative Stress and Low-Grade Inflammation in Elderly Patients","POXI-AGEING","Inclusion Criteria:\n\n* Male or female, aged 70 to 90, consulting the Nantes CHU CANGC (Bellier Hospital) and who has an indication for a blood test scheduled as part of routine care within 4 months according to the clinician.\n* Clinical Frailty Scale (CFS) score less than or equal to 4 (i.e. threshold for identifying frail elderly people).\n\nExclusion Criteria:\n\n* Opposition to participation in the study\n* Indication for emergency blood sampling in the city\n* Use of a wheelchair or with a proven disability\n* Criteria for undernutrition: weight loss of more than 5% in the last month or more than 10% in the last 6 months and\u002For BMI strictly less than 22 kg\u002Fm2.\n* Tobacco consumption\n* Diabetes\n* Any type of active and\u002For treated cancer less than 5 years old\n* Chronic inflammation pathology\n* Clinically significant infectious or inflammatory episode ended at least one month ago\n* Long-term or last-month corticosteroid therapy\n* Antioxidants or trace elements taken in the last 3 months\n* Patient not affiliated to a Social Security system\n* Patient deprived of liberty by judicial or administrative decision\n* Patients under guardianship or trusteeship","90 Years",{"count":434,"type":20},30,"OBSERVATIONAL","Sarcopenia, an age-related decline in muscle function, are thought to be influenced by oxidative stress and low-grade inflammation, resulting in significant muscle mass reduction and altered physical performance. Indeed, oxidative stress and chronic inflammation in older adults are key factors contributing to metabolic protein disturbances, DNA mutations, and skeletal muscle decline during aging. Additionally, reduced food intake can lead to malnutrition, exacerbating muscle protein loss, oxidative stress and chronic inflammation.\n\nRecent research has shown that a nutritional intervention, i.e. antioxidant supplementation (e.g., vitamins C, E, zinc, selenium) can reduce muscle damage in Facioscapulohumeral Dystrophy (FSHD) by correcting mitochondrial dysfunction and inflammation with a beneficial effect on physical performance and have led to the development of a personalized antioxidant supplementation model, supported by clinical trials (NCT02622438).\n\nAlthough antioxidant supplementation appears beneficial for FSHD patients, its effects on age-related muscle decline remain unclear. This study aims to explore correlation between oxidative stress, inflammation, nutritional status and physical performance in older individuals. The findings will help establish the physiological basis for a potential antioxidant therapy for age-related muscle deterioration.",[438,439,230,440,26],"Inflammation","Oxydative Stress","Older Patient",[442,443,444,445,67],"inflammation","oxydative stress","sarcopenia","older patient","2025-05-12",{"date":448,"type":35},"2025-05-20",{"date":450,"type":20},"2025-09-01",{"date":452,"type":20},"2027-05-01",{"name":454,"class":42},"Nantes University Hospital",{"id":456,"slug":457,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":435,"phases":4,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":243,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":4},"100588684","impact-of-sleep-disorders-and-digital-support-on-older-peoples-health-100588684","NCT06944600","Impact of Sleep Disorders and Digital Support on Older People's Health","The Role of Sleep Disorders in the Motoric and Cognitive Trajectories of Older Physically Frail Sarcopenic and Healthy Active Subjects","SOMNUS-DARE","Inclusion Criteria:\n\n* Age ≥ 65 years;\n* MMSE score adjusted by age and education ≥ 25\u002F30;\n* Absence of mobility-disability;\n* Absence of need for assistance with Basic Activities of Daily Living (according to the ICFSR International Clinical Practice Guidelines).\n\nExclusion Criteria:\n\n* Individuals with specific clinical conditions that make the intervention unsafe (I.e., severe diseases, unstable health status);\n* Individuals whose adherence to the protocol might be low due to clinical (E.g., cognitive impairment, dialysis) and non-clinical (E.g., plans to relocate out of the study area within the next 3 years) reasons;\n* Individuals unable or unwilling to provide informed consent;\n* Consumption of more than 14 alcoholic drinks per week \\[one alcoholic drink (equal to 14.0 grams of pure alcohol) corresponds to 36 cc of beer (5% alcohol content), 24 cc of malt liquor (7% alcohol content), 15 cc of wine (12% alcohol content), 4.5 cc of distilled spirit or liquor (40% alcohol content)\\];\n* Difficulty in communicating with the study staff due to speech, language, or (non-corrected) hearing and vision problems;\n* Severe arthritis (E.g., awaiting joint replacement) that would interfere with the ability to fully participate in the study;\n* Lung disease requiring regular use of supplemental oxygen;\n* Severe cardiovascular disease (including New York Heart Association \\[NYHA\\] class III or IV, clinically significant congestive heart failure and valvular disease, history of cardiac arrest, presence of an implantable defibrillator or pacemaker, uncontrolled angina);\n* Upper and\u002For lower extremity amputation;\n* Peripheral arterial disease Lériche-Fontaine 3 or 4;\n* Renal disease requiring dialysis;\n* Current enrolment in another study involving lifestyle, nutrition, or pharmaceutical interventions;\n* Further medical, psychiatric, or behavioural factors that in the judgment of the principal investigator may interfere with the study participation;\n* Further possible illnesses affecting the life expectancy and reducing it to less than 24 months, corresponding to the study's length;\n* Clinical judgment concerning safety or non-compliance, as well as the conditions for which the use of the Sleep Profiler is not recommended (sensitivity of skin or scalp and\u002For open wounds on the forehead or scalp, allergic reactions to extended exposure to synthetic fabrics (e.g., polyester, rayon), upper respiratory infection or congestion, head circumference less than 21 or greater than 25 inches, forehead vertical measurement (from top of eyebrows to hairline) less than or equal to 2 inches or horizontal measurement (from hairline to hairline) less than or equal to 6 inches).\n* SPPB score \\\u003C3 at baseline.",{"count":464,"type":20},300,"The goal of this observational study is to learn about the effects of sleep disorders on health and ageing in older people over the age of 65.\n\nThe main question it aims to answer is: How do sleep disorders impact the motoric and cognitive ageing trajectories of older individuals? Participants will undergo a set of instrumental, laboratory and clinical diagnostic examinations to comprehensively assess the impact of sleep disorders on health.",[467,229,468,469,26,470,471],"Sleep Disorders","Cognitive Impairment","Quality of Life","Digital Health","Multidisciplinary Approach","2025-04-17",{"date":474,"type":35},"2025-04-25",{"date":476,"type":20},"2025-05",{"date":478,"type":20},"2027-11",{"name":480,"class":42},"University of Parma",{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":435,"phases":4,"briefSummary":490,"conditions":491,"keywords":494,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":43},"100582470","the-beijing-longitudinal-disability-survey-in-community-elderly-100582470","NCT06863727","The Beijing Longitudinal Disability Survey in Community Elderly","BLINDSCE","Inclusion Criteria:\n\n* Community-dwelling adults aged 65 years or older who reside in Beijing.\n* Participants who sign an institutionally approved informed consent.\n\nExclusion Criteria:\n\n* Participants with severe mental disorders and serious medical conditions preventing study investigation\n* Participants undergoing long-term professional treatment for physical function and cognitive functioning, such as hospitalization or rehabilitation.",{"count":489,"type":20},1962,"The goal of this observational study is to establish the prospective cohort of the Beijing Longitudinal Disability Survey in Community Elderly (BLINDSCE) to explore the high-risk factors and preventive interventions for disability and cognitive impairment among community-dwelling adults aged 65 years and over. The main question it aims to answer is:\n\n* What are the high-risk factors able to predict the incidence and advance of disability and cognitive impairment in community-dwelling adults aged 65 years and over?\n* What are the categories of function and cognitive performance trajectory in community-dwelling adults aged 65 years and over?",[26,492,468,229,493],"Disability","Intrinsic Capacity",[26,492,468,495,496],"Community","Cohort","2025-03-03",{"date":499,"type":35},"2025-03-07",{"date":501,"type":35},"2023-08-07",{"date":503,"type":20},"2028-07-31",{"name":505,"class":42},"Xuanwu Hospital, Beijing",{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":345,"healthyVolunteers":15,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":21,"phases":514,"briefSummary":515,"conditions":516,"keywords":517,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":532},"100561910","comparing-vascular-responses-to-resistance-exercise-with-and-without-blood-flow-restriction-in-young-and-older-adults-100561910","NCT06596304","Comparing Vascular Responses to Resistance Exercise with and Without Blood Flow Restriction in Young and Older Adults","Comparing Macro- and Microvascular Responses to Acute Resistance Exercise with and Without Blood Flow Restriction in Young and Older Adults: a Parallel Group Crossover Randomized Trial","HOLD TIGHT",{"count":347,"type":20},[23],"Aging leads to declines in functional capacity and effort tolerance. Muscle strength remains stable from ages 25 to 50 but declines significantly after age 60, affecting activities like stair climbing and walking, reducing autonomy and independence. While muscle atrophy is a significant factor, macrovascular endothelial dysfunction also impairs skeletal muscle performance in older adults. Nitric oxide (NO), produced by endothelial cells, regulates vascular homeostasis and contractile function. NO enhances muscle fiber shortening velocity, reduces twitch time-to-peak contraction, and increases the rate of force development. Aging-related endothelial dysfunction reduces NO availability, leading to reduced muscle mass and sarcopenia via decreased skeletal muscle perfusion. Increased arterial stiffness disrupts ventricular-vascular coupling, reducing cardiac output and contributing to age-related muscle weakness. Additionally, microvascular function decreases with age, contributing to altered physical work perception and reduced function. Low capillary density is linked to reduced walking speed in older adults and reduced walking time in peripheral arterial disease patients, supporting the microvasculature\\'s role in functional performance. Reduced muscle mass also increases central hemodynamic load, impacting arterial stiffness and cardiac function.\n\nResistance training (RT) is recommended to mitigate aging effects like loss of strength and muscle mass and reduce cardiovascular risk and all-cause mortality. Guidelines suggest 1-3 sets of 8-12 repetitions at 60-80% of the individual\\'s repetition maximum (1RM), performed at least twice a week. However, older adults with osteoarthritis and cardiovascular conditions often cannot tolerate high mechanical stress and are prescribed lower intensity-resistance training (LIRT) at 40-50% of 1RM, typically yielding negligible muscle hypertrophy or strength gains. Blood flow restriction (BFR) training, which applies pressure bands to restrict blood flow during LIRT, increases muscle volume and strength. While BFR shows promise, it can cause acute increases in arterial stiffness and blood pressure in older adults, necessitating caution in its prescription.\n\nThis study aims to compare macrovascular and microvascular function responses to acute resistance exercise with and without BFR in young and older adults. We hypothesize that older adults will show a more pronounced increase in macrovascular and microvascular dysfunction following resistance exercise compared to younger participants. In this parallel group randomized controlled trial, participants will be randomly assigned to either LIRT-BFR or high-intensity resistance training (HIRT). Each participant will attend three sessions: a familiarization session and two experimental sessions involving the randomized exercise conditions. Measurements of brachial blood pressure, heart rate, and macrovascular and microvascular function will be taken at rest and during recovery periods post-exercise.",[26,354],[518,164,519,520,521,522,523],"blood flow restriction","microvascular function","arterial stiffness","blood pressure","young adults","older adults","2024-10-19",{"date":526,"type":35},"2024-10-23",{"date":528,"type":20},"2024-10",{"date":530,"type":20},"2025-07",{"name":368,"class":42},2]